Table 2. Major Characteristics of Fifteen Controlled Researches on Peritoneal Carcinomatosis (PC) from Colorectal Cancer (CRC) Treated with Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) versus Surgery alone with Systemic Chemotherapy (SC) and/or Early Postoperative Intraperitoneal Chemotherapy (EPIC).
| Author/ Year/ Country | Participating Institutions |
Study Period | Design | Level of Evidence | Number of CRC PC | Treatment strategy | |
|---|---|---|---|---|---|---|---|
| HIPEC group | Control group | ||||||
| Elias D/ 2001/ France [35] | 1 | 1993-1999 | prospective | IIa | 55 (55/64) | HIPEC 27 pts HIPEC: 1. MMC (5, 8, or 10 mg/L) for 1 h between 41 °C and 44 °C using the Coliseum technique. 2. MMC (20 mg/m2) + DDP (200 mg/m2) for 1 h between 41 °C and 44 °C using the Coliseum technique. EPIC: MMC (10 g/m2) on Day 1 + 5-FU (500 mg/m2) form Day 2 to Day 6 lasted 23 h No SC |
EPIC37 pts EPIC: MMC (10 g/m2) on Day 1 + 5-FU (500 mg/m2) form Day 2 to Day 6 lasted 23 h No HIPEC No SC |
| Elias D/ 2007/ France [36] | 1 | 1999-2002 1994-2000 |
prospective | IIa | 46 (46/46) | CRS+HIPEC 23 pts HIPEC: L-OHP (460 mg/m2) for 35 min between 42-44°C using the Coliseum technique; Before starting HIEPC, 5-FU (400 mg/m2) and LV (20 mg/m2) by intravenous perfusion. EPIC: MMC (10 mg/m2) at day 0, then 5-FU (650 mg/m2) for the next 4days SC (not reported) |
EPIC 23 pts EPIC: MMC (10 mg/m2) at day 0, then 5-FU (650 mg/m2) for the next 4days SC (not reported) No HIPEC |
| Elias D/ 2009/ France [28] | 6 (Only one centre conducted HIPEC, the rest of 5 as a control) |
1998-2003 | retrospective | IIa | 96 (96/96) | Neoadjuvant IPC+CRS+HIPEC+SC 48 pts Neoadjuvant IPC: L-OHP or CPT-11 (not reported the detailed regimen) HIPEC: L-OHP (460 mg/m2) over 30 min at 43°C using the Coliseum technique. Before starting HIEPC, 5-FU 400 mg/m2 and LV 20 mg/m2 by intravenous perfusion. SC: 1. FU Plus CPT-11 or L-OHP, LV; 2. Cap Plus L-OHP; 3. CPT-11 plus C225 and CPT |
Surgery and/or SC 48 pts SC: 1. FU Plus CPT-11 or L-OHP, LV; 2. Cap Plus L-OHP; 3. CPT-11 plus C225 and CPT No HIPEC No EPIC |
Note: CRC: colorectal cancer; PC: peritoneal carcinomatosis; Pts: patients; MMC: mitomycin C; DDP: cisplatin; FU: fluorouracil; LV: leucovorin; L-OHP: oxaliplatin; CPT-11: irinotecan; Cap: capecitabine; C225: cetuximab; CPT: camptothecin; BEV: bevacizumab; DXL: docetaxel; CBP: carboplatin; PAN: panitumumab;